Global markets Global equities pushed higher last week despite a rising CV-19 case count, with investors taking heart from a continuing ‘re-opening’ bounce in the data, further somewhat encouraging drug news and – most important of all – several major U.S. states still resisting pressure to …

Global markets Global equities managed to shrug off mounting U.S. virus concerns last week and instead focus on better than expected ‘re-opening’ economic data. Of course, the Fed chipped in with further “whatever it takes” supportive comments, and another drug company announced early promising vaccine results. …

Global markets The continued rise in U.S. COVID-19 cases further undermined risk sentiment last week – even though, as U.S. President Trump noted, increased testing appears an important factor behind the rise (although the percentage of positive tests is also increasing). The S&P 500 lost 2.9%, …

Global markets Global equities tried hard to remain positive last week even as new CV-19 cases continued to emerge in Beijing and some U.S. states. After the previous Thursday’s collapse in prices, equities bounced higher early last week following the Fed’s (rehashed) announcement that it would …

Global markets Good news is good news. Bad news is good news. And no news is good news also! Global equities pushed higher last week as positive ‘re-opening’ data, no second waves, and confidence in unrelenting fiscal and monetary stimulus continued to buoy investor sentiment. Key …

Global markets Risk-on sentiment prevailed across global markets last week – so much so that even previously neglected sectors such as financials began to attract interest. Key drivers were upbeat comments from JP Morgan CEO Jamie Dimon, and the fact Trump failed to follow through on …

Global markets It was risk on again last week in global markets as seemingly encouraging COVID-19 vaccine trials got investors excited early on, before experts started to raise questions about the significance of the results. Either way, the share price of the company in question, Moderna, …

Global markets Last week I headlined my Bites report ‘Testing resistance’, given the focus on whether the S&P 500 could break through recent highs of 2,930 and march onward to 3,000. As it turned out, the market did test, but failed to break, this resistance, given …

Global markets Global equities continued to remain focused on re-opening hopes last week, disregarding apocalyptic economic data from most corners of the world outside of China. The fact Wall Street could rally in the face of 20 million job losses in April, and a surge in …

Global markets Despite a strong rebound in oil prices, last week was perhaps a reality check for global markets as the depth of the downturn in both economic growth and corporate earnings became ever more evident. U.S. Q1 GDP, consumer confidence and manufacturing conditions were all …